Morosini María-Isabel, Loza Elena, del Campo Rosa, Almaraz Felisa, Baquero Fernando, Cantón Rafael
Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Antimicrob Agents Chemother. 2003 Aug;47(8):2692-5. doi: 10.1128/AAC.47.8.2692-2695.2003.
The activity of garenoxacin was assessed against 412 Streptococcus pneumoniae isolates (49.3% from the adult population). Overall penicillin, erythromycin, and ciprofloxacin (MIC, >/=4 micro g/ml) resistance was 51.7, 35.4, and 1.5%, respectively. For all isolates, the garenoxacin MIC was </=1 micro g/ml. Amino acid replacements in GryA (Ser81-->Phe or Tyr), ParC (Ser79-->Phe or Tyr; Asp83-->Gly; Lys137-->Asn), and ParE (Ile460-->Val; Asp435-->Asn), alone or in combination, were ascribed to the reduced garenoxacin susceptibility (MIC range, 0.5 to 1 micro g/ml) found in four isolates. The low impact of these mutations on garenoxacin activity envisages the possible coverage of S. pneumoniae populations resistant to preexisting quinolones.
对412株肺炎链球菌分离株(49.3%来自成人)进行了加替沙星活性评估。总体而言,青霉素、红霉素和环丙沙星(MIC,≥4μg/ml)的耐药率分别为51.7%、35.4%和1.5%。对于所有分离株,加替沙星的MIC≤1μg/ml。在四个分离株中发现,GryA(Ser81→Phe或Tyr)、ParC(Ser79→Phe或Tyr;Asp83→Gly;Lys137→Asn)和ParE(Ile460→Val;Asp435→Asn)中的氨基酸替换单独或联合出现,被认为与加替沙星敏感性降低(MIC范围为0.5至1μg/ml)有关。这些突变对加替沙星活性的影响较小,这意味着加替沙星可能覆盖对现有喹诺酮耐药的肺炎链球菌群体。